Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01844687 · ClinicalTrials.gov registry record · Phase 2
Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana
A Phase 2 study of Smoking, Marijuana, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT01844687: Completed Phase 2 study of Smoking, Marijuana, sponsored by National Institute on Drug Abuse (NIDA).
NCT01844687 is a Phase 2 study of Smoking, Marijuana that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01844687, a Phase 2 study of Smoking, Marijuana, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of this study is to assess the effects of oral cannabidiol (CBD; 0, 200, 400, 800 mg) on smoked marijuana's (0, 5.6% THC) subjective, reinforcing, cognitive, and cardiovascular effects. This experiment is expected to reveal CBD's intrinsic effects when combined with placebo marijuana, as well as its ability to modulate the behavioral effects of active marijuana.
Primary Outcome
Participants rated how much they felt having a "high" feeling from smoked marijuana using a visual analog scale 1-100 mm, 1 (Not at all) - 100 (extremely).
Conditions Studied
Interventions
- DRUG CBD
Study Locations (3)
Kentucky
- University of Kentucky, Straus Behavioral Research Bldg., 515 Oldham Ct. - Lexington
New York
- Marijuana Outpatient Lab 1051 Riverside Dr. Unit #120 - New York
South Carolina
- Center for Drug and Alcohol Programs, Room 459 North, 67 President St. - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
What the finished NCT01844687 record still lists
NCT01844687 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Smoking, Marijuana appearing as the primary indexed condition, and to 1 intervention - of which CBD is the first listed.
NCT01844687 reports a single indexed study location in Kentucky, New York, South Carolina.
Frequently Asked Questions
What is clinical trial NCT01844687 about?
NCT01844687 is a clinical study titled "Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana". The objective of this study is to assess the effects of oral cannabidiol (CBD; 0, 200, 400, 800 mg) on smoked marijuana's (0, 5.6% THC) subjective, reinforcing, cognitive, and cardiovascular effects. This experiment is expected to reveal CBD's intrinsic effects when combined with placebo marijuana, ...
What is the current status of trial NCT01844687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2013-05. Estimated completion is 2014-10.
What conditions does trial NCT01844687 study?
This clinical trial studies the following conditions: Smoking, Marijuana.
What interventions are being tested in trial NCT01844687?
The interventions under investigation include: CBD (DRUG).
Who is sponsoring clinical trial NCT01844687?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01844687 being conducted?
This trial has 3 study locations across Kentucky, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01844687's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia